“Obviously, we can’t know what the differences are between the North American and the non–North American groups,” Dr. French said. “But we can speculate. And in North America, with EEG monitoring, we can confirm that the patients actually have epilepsy before we enroll them in trials. In other areas, that’s less likely to happen. There may be different background drugs that are contributing to their seizures, etc. I think we have to be very careful about looking at who was involved in the trials so that we can get valid, interpretable data.”
—Jack Baney